Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Belite Bio, Inc. Sponsored ADR (BLTE : NSDQ)

• Company Description    Belite Bio Inc. is a clinical stage biopharmaceutical drug development company focused on novel therapeutics targeting currently untreatable eye diseases involving retinal degeneration, such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease, and metabolic diseases. Belite Bio Inc. is based in SAN DIEGO. Number of Employees: 23

• Price / Volume Information    Yesterday's Closing Price: $137.30 Daily Weekly Monthly 20 Day Moving Average: 121,893 shares Shares Outstanding: 39.97 (millions) Market Capitalization: $5,487.19 (millions) Beta: -1.19 52 Week High: $200.00 52 Week Low: $56.10 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -16.51% -20.59% 12 Week -27.18% -32.68% Year To Date -14.17% -17.09%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 12750 HIGH BLUFF DRIVE SUITE 475 - SAN DIEGO,CA 92130 USA ph: 858-246-6240 fax: - ir@belitebio.com http://www.belitebio.com

• General Corporate Information    Officers Yu-Hsin Lin - Chief Executive Officer and Chairman of the Board? Hao-Yuan Chuang - Chief Financial Officer Nathan L. Mata - Chief Scientific Officer Wan-Shan Chen - Director Xiao - Hui Chen - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 07782B104 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/10/26 Share - Related Items Shares Outstanding: 39.97 Most Recent Split Date: (:1) Beta: -1.19 Market Capitalization: $5,487.19 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.63 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.20 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 42.40% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/10/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 6.90 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 24.44% vs. Previous Quarter: 10.53% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/26 - -13.14 12/31/25 - -19.49 09/30/25 - -34.28 ROA 03/31/26 - -12.88 12/31/25 - -19.05 09/30/25 - -33.05 Current Ratio 03/31/26 - 33.71 12/31/25 - 50.02 09/30/25 - 34.37 Quick Ratio 03/31/26 - - 12/31/25 - 50.02 09/30/25 - 34.37 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Book Value 03/31/26 - 19.91 12/31/25 - 20.54 09/30/25 - 8.61 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00

Powered by Zacks Investment Research ©